Medicinal Cannabis NZ Guide

Medicinal-cannabis clinical trials

Medicinal-cannabis clinical trials. Explain phases, controls, registration and publication. The page must give the reader a usable method, checklist or decision

Clinical trials are the engine that separates a regulated medicine from a herbal remedy. For medicinal cannabis in New Zealand, the rules are strict: a product cannot be prescribed, dispensed, or imported unless it has been through the same testing framework as any other pharmaceutical. This page explains how those trials work, how to read the evidence, and how to check whether a product you are considering has actually been through the process. It is written for patients, whānau, clinicians, pharmacists, and anyone who needs to tell a verified claim from a marketing claim.

What counts as a medicinal-cannabis clinical trial in New Zealand

A clinical trial in New Zealand is a formal research study in human participants, conducted under the rules of the New Zealand Ministry of Health and the Health and Disability Ethics Committees (HDEC). For medicinal cannabis, the trial must use a product that meets Good Manufacturing Practice (GMP) standards and is approved under the Misuse of Drugs Act 1975. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (part of Medsafe), sets the quality and licensing rules.

Under the scheme (effective 1 April 2020, per the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018), a product can be prescribed only if it is a “controlled drug” manufactured to GMP and notified to the Ministry of Health. The raw plant material, if prescribed, is dispensed through a pharmacy as a manufactured pharmaceutical product, not through a dispensary and not for smoking. This is the single most important boundary: a prescription does not legalise possession of unregulated plant material.

What a clinical trial actually is

A clinical trial is a structured experiment in humans, designed to answer a specific question about a medicine, product, or intervention. In the context of medicinal cannabis, the question is usually whether a product containing CBD, THC, or both is safe and effective for a defined condition (for example, chronic pain or epilepsy). The trial compares the product against a control, which can be a placebo, an existing treatment, or a different dose of the same product. The outcome is measured objectively, and the results are analysed statistically to decide whether any difference is real or due to chance.

The phases of medicinal-cannabis trials

Clinical trials run in four phases, each with a different question. Understanding the phase tells you how much evidence exists and what kind of claim a company can legally make.

Phase 1, Safety and dosing - Participants: small group (usually 20-80 healthy volunteers or patients). - Goal: find a safe dose range and identify side effects. - Relevance to cannabis: establishes maximum tolerated dose of THC or CBD in humans; often done with single-dose or short-course exposure. - What you can conclude: “The product is safe enough to test in patients,” not “it works.”

Phase 2, Early efficacy - Participants: 100-300 patients with the target condition. - Goal: test whether the product has a measurable effect and refine dosing; may be open-label or randomised. - Relevance: many CBD/THC products stop here; positive phase 2 results are not proof of efficacy.

Phase 3, Confirmatory trials - Participants: hundreds to thousands of patients, often multi-centre. - Goal: confirm efficacy, monitor adverse effects, compare with standard treatment or placebo. - Relevance: this is the phase that produces the evidence used in prescribing decisions and product registration.

Phase 4, Post-marketing surveillance - Participants: real-world patients after approval. - Goal: monitor long-term safety and rare adverse effects. - Relevance: in NZ, this is ongoing once a product is approved and prescribed.

CONTROL: A “control” is a comparison group that does not receive the active treatment. In medicinal-cannabis trials, the control is usually a placebo that looks and tastes identical (e.g., placebo oil or placebo flower) so patients and assessors cannot tell the difference. Blinding means neither the patient nor the researcher knows who gets active treatment until the trial ends. In some trials, an active comparator (another medicine) is used instead of placebo; this tests whether cannabis is at least as good as the standard treatment, not just better than nothing.

REGISTRATION: In New Zealand, the primary registry is the Australian New Zealand Clinical Trials Registry (ANZCTR), and most trials also register internationally with ClinicalTrials.gov. Registration before enrolment is mandatory for publication in reputable journals. Check the registry entry for the trial ID, sponsor, primary outcome, and whether the trial is recruiting.

PUBLICATION: A trial is only as good as its publication record. Use PubMed, Google Scholar, and the Cochrane Library to find systematic reviews and peer-reviewed trials. Beware of “research” published in predatory journals or by companies marketing a product.

PRACTICAL METHOD: Evaluate a medicinal cannabis product using the same framework a pharmacist would use. First, check the product is listed on the NZ Formulary and has a Medsafe approval or a Section 29 exemption. Second, check the THC and CBD content in mg/g and the THC:CBD ratio; this determines the expected effect and side-effect profile. Third, check the GMP certification status, which is mandatory for legal supply. Fourth, check the onset and duration of the product form (flower vs oil). Fifth, verify the product’s stability and batch testing certificate. If a product fails any of these five checks, it is not a legally dispensable medicinal cannabis product in New Zealand.

What this page is for

If you are a patient, a clinician, a pharmacist, or a policy reader, this page answers one question: how do medicinal-cannabis clinical trials actually work in New Zealand? It covers the trial phases, the controls that make results trustworthy, how a medicine gets registered, and how to read published evidence without being misled by marketing.

This page is part of the Medicinal Cannabis NZ Guide. It sits alongside the science and industry overview, which covers the wider evidence base and commercial landscape. Here, the focus is the clinical-trial machinery and how to judge a cannabis study yourself.

What a clinical trial is and why it matters

A clinical trial is a controlled experiment on humans. In New Zealand, a medicinal-cannabis product used in a trial is treated as an unapproved medicine unless it has been approved by Medsafe under the Medicinal Cannabis Scheme. The scheme was created by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, which took effect on 1 April 2020 (New Zealand Ministry of Health, 2020). Under that Act, a medical practitioner can prescribe a CBD or THC product that meets GMP standards, but the product must be an approved pharmaceutical, not raw plant material bought elsewhere.

The key distinction: “legal medicinal cannabis” in New Zealand means a manufactured pharmaceutical product prescribed by a doctor and dispensed by a pharmacy. It does not mean a general licence to use cannabis. Raw flower is available, but it is prescribed and dispensed through a pharmacy, not a dispensary. The Ministry of Health’s Medicinal Cannabis Agency (MCA), part of Medsafe, runs the scheme.

What a clinical trial actually tests

A clinical trial is a structured experiment on humans. Its job is to answer one question: does this intervention work, and is it safe enough to use in ordinary practice? In medicinal cannabis, the intervention can be a flower, an oil, a capsule, or an isolate. The trial compares it against a control, usually a placebo, occasionally an active comparator, and measures predefined outcomes such as pain scores, seizure frequency, or quality-of-life changes.

Trials are not the same as a prescription. A prescription is a clinical decision for an individual patient; a trial is a research protocol designed to generate generalisable evidence. The results of trials feed into the evidence base that clinicians use, but they do not guarantee that a product will work for any given person.

How to read a trial report

When you are reading a medicinal-cannabis trial, ask four questions before you accept its conclusion:

  1. Was it randomised and controlled? A randomised controlled trial (RCT) compares the product against a placebo or an active comparator. Uncontrolled observational studies cannot prove cause and effect.
  2. Was the product standardised? The label must state the exact THC and CBD content in mg/g or %. If the product is not standardised, the results cannot be replicated.
  3. Who funded it? Industry-funded trials are common in this field; check the conflicts of interest and whether the authors had access to raw data.
  4. What was the outcome measured? Patient-reported pain scores, quality-of-life scales, and seizure diaries are valid, but they are not the same as objective biomarkers. Be clear about what was measured.

What is a medicinal-cannabis clinical trial?

A medicinal-cannabis clinical trial is a structured research study that tests a cannabis-derived product (flower, oil, capsule, or isolate) in humans to determine whether it is safe and effective for a specific medical condition. In New Zealand, the legal framework for these trials sits under the Misuse of Drugs Act 1975 and the Medicines Act 1981, and the regulator is Medsafe, which operates the Medicinal Cannabis Agency (MCA). The key distinction: a clinical trial is research, not treatment. It answers a question under controlled conditions; it does not guarantee a patient access to a product.